B+
Bull case
25%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
ARDT
Ardent HealthANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$12.77
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$8.75
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-05
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+74.4
Score
AI commentary
The evidence mix is mixed: Q2 results and reaffirmed guidance were constructive, while the September 4 SEC filing revision is a negative reporting-quality and valuation signal. Social coverage is absent, and analyst, options, short-interest, employee-rating, and verified market-reaction data are unavailable; confidence is therefore moderate-low and primarily filing-driven.
RankAlpha Sentiment Codex - 2026-09-05
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-04eventQ2 results reaffirmed FY2026 guidanceMedium impact
Ardent reported Q2 revenue of $1.62 billion, adjusted EBITDA of $115 million, operating cash flow of $197 million, and reaffirmed FY2026 revenue guidance of $6.4-$6.7 billion and adjusted EBITDA guidance of $485-$535 million despite a lower volume outlook [#SEC-8K-2026-08-04].
2026-09-04catalystNon-GAAP revision creates valuation overhangMedium impact
The September 4 8-K removed $97.7 million of prior-period non-GAAP adjustments, reducing reported 2025 adjusted EBITDA from $545.0 million to $447.3 million. The company stated there is no impact on 2026 results, GAAP statements, cash flows, or financial condition, but comparability and reporting credibility may be questioned [#8-K-2026-09-04].
2026-12-04catalystVolume and procedure pressureMedium impact
Q2 admissions declined 1.0% year over year, and management cited lower surgeries and admissions while incorporating a lower volume outlook into reaffirmed guidance [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-05 • Updated nightlySource: Internal modelMethodology